

PUBLICATIONS:

A. Pubmed indexed:

Summary: 172 articles overall (41 first authorships and 7 last authorships).

1. Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up. Gandaglia G, Fossati N, Stabile A, **Bandini M**, Rigatti P, Montorsi F, Briganti A. *Eur Urol*. 2016.
2. Effect of Stage Migration on Bladder Cancer: A Slow but Steady Improvement in Long-Term Survival Rates After Radical Cystectomy in Previous 25 Years. Moschini M, Luzzago S, Cazzaniga W, Cucchiara V, **Bandini M**, Damiano R, Soria F, Klatte T, Shariat SF, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A. *Clin Genitourin Cancer*. 2016.
3. Can the multiphasic computed tomography be useful in the clinical management of small renal masses? Gaudiano C, Schiavina R, Vagnoni V, Busato F, Borghesi M, **Bandini M**, Di Carlo M, Brunocilla E, Martorana G, Golfieri R. *Acta Radiol*. 2016.
4. Early Post-Operative Radiotherapy is Associated with Worse Functional Outcomes in Prostate Cancer Patients. Zaffuto E, Gandaglia G, Fossati N, Dell'Oglio P, Moschini M, Cucchiara V, Suardi N, Mirone V, **Bandini M**, Shariat SF, Karakiewicz PI, Montorsi F, Briganti A. *J Urol*. 2016.
5. Pure but Not Mixed Histologic Variants Are Associated With Poor Survival at Radical Cystectomy in Bladder Cancer Patients. Moschini M, Shariat SF, Lucianò R, D'Andrea D, Foerster B, Abufaraj M, **Bandini M**, Dell'Oglio P, Damiano R, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A. *Clin Genitourin Cancer*. 2017.
6. Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy. Moschini M, Foerster B, Abufaraj M, Soria F, Seisen T, Roupret M, Colin P, De la Taille A, Peyronnet B, Bensalah K, Herout R, Wirth MP, Novotny V, Chlosta P, **Bandini M**, Montorsi F, Simone G, Gallucci M, Romeo G, Matsumoto K, Karakiewicz P, Briganti A, Shariat SF. *World J Urol*. 2017.

7. Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer. Gandaglia G, Fossati N, Zaffuto E, **Bandini M**, Dell'Oglio P, Bravi CA, Fallara G, Pellegrino F, Nocera L, Karakiewicz PI, Tian Z, Freschi M, Montironi R, Montorsi F, Briganti A. *Eur Urol.* 2017.
8. An Explanatory Case on the Limitations of Lymph Node Staging in Recurrent Prostate Cancer. **Bandini M**, Gandaglia G, Fossati N, Montorsi F, Briganti A. *Urol Case Rep.* 2017.
9. External Beam Radiotherapy Affects Serum Testosterone in Patients With Localized Prostate Cancer. Pompe RS, Karakiewicz PI, Zaffuto E, Smith A, **Bandini M**, Marchioni M, Tian Z, Leyh-Bannurah SR, Schiffmann J, Delouya G, Lambert C, Bahary JP, Beauchemin MC, Barkati M, Ménard C, Graefen M, Saad F, Tilki D, Taussky D. *J Sex Med.* 2017.
10. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Gandaglia G, Boorjian SA, Parker WP, Zaffuto E, Fossati N, **Bandini M**, Dell'Oglio P, Suardi N, Montorsi F, Karnes RJ, Briganti A. *Eur Urol.* 2017.
11. Obesity and prostate cancer. **Bandini M**, Gandaglia G, Briganti A. *Curr Opin Urol.* 2017.
12. Salvage surgery for nodal recurrent prostate cancer **Bandini M**, Gandaglia G, Briganti A. *Curr Opin Urol.* 2017.
13. Marital status and gender affect stage, tumor grade, treatment type and cancer specific mortality in T1-2 N0 M0 renal cell carcinoma. Marchioni M, Martel T, **Bandini M**, Pompe RS, Tian Z, Kapoor A, Cindolo L, Autorino R, Briganti A, Shariat SF, Schips L, Karakiewicz PI. *World J Urol.* 2017.
14. New surgical approaches for clinically high-risk or metastatic prostate cancer. Dell'Oglio P, Stabile A, Gandaglia G, Zaffuto E, Fossati N, **Bandini M**, Suardi N, Karakiewicz PI, Shariat SF, Montorsi F, Briganti A. *Expert Rev Anticancer Ther.* 2017.

15. Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era. Marchioni M, **Bandini M**, Pompe RS, Tian Z, Martel T, Kapoor A, Cindolo L, Berardinelli F, Briganti A, Shariat SF, Schips L, Karakiewicz PI. *Int Urol Nephrol*. 2017.
16. The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pT2-3 non-metastatic renal cell carcinoma treated with radical nephrectomy. Marchioni M, **Bandini M**, Pompe RS, Martel T, Tian Z, Shariat SF, Kapoor A, Cindolo L, Briganti A, Schips L, Capitanio U, Karakiewicz PI. *BJU Int*. 2017.
17. Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy. **Bandini M**, Smith A, Zaffuto E, Pompe RS, Marchioni M, Capitanio U, Chun FK, Kapoor AB, Shariat SF, Montorsi F, Briganti A, Karakiewicz PI. *World J Urol*. 2017.
18. Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis. **Bandini M**, Pompe RS, Marchioni M, Tian Z, Gandaglia G, Fossati N, Tilki D, Graefen M, Montorsi F, Shariat SF, Briganti A, Saad F, Karakiewicz PI. *World J Urol*. 2017.
19. Identifying the candidate for super extended staging pelvic lymph node dissection among patients with high-risk prostate cancer. Gandaglia G, Zaffuto E, Fossati N, **Bandini M**, Suardi N, Mazzone E, Dell'Oglio P, Stabile A, Freschi M, Montorsi F, Briganti A. *BJU Int*. 2017.
20. First North American validation and head-to-head comparison of four preoperative nomograms for prediction of lymph node invasion before radical prostatectomy. **Bandini M**, Marchioni M, Pompe RS, Tian Z, Gandaglia G, Fossati N, Abdollah F, Graefen M, Montorsi F, Saad F, Shariat SF, Briganti A, Karakiewicz PI. *BJU Int*. 2017.
21. Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study. **Bandini M**, Pompe RS, Marchioni M, Zaffuto E, Gandaglia G, Fossati N, Cindolo L, Montorsi F, Briganti A, Saad F, Karakiewicz PI. *Int Urol Nephrol*. 2017.

22. Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study. Marchioni M, **Bandini M**, Preisser F, Tian Z, Kapoor A, Cindolo L, Primiceri G, Berardinelli F, Briganti A, Shariat SF, Schips L, Karakiewicz PI. *Eur Urol Focus*. 2017.
23. Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification. Leyh-Bannurah SR, Budäus L, Zaffuto E, Pompe RS, **Bandini M**, Briganti A, Montorsi F, Schiffmann J, Shariat SF, Fisch M, Chun F, Huland H, Graefen M, Karakiewicz PI. *Urol Oncol*. 2018.
24. A Head-to-head Comparison of Four Prognostic Models for Prediction of Lymph Node Invasion in African American and Caucasian Individuals. **Bandini M**, Marchioni M, Preisser F, Nazzani S, Tian Z, Fossati N, Gandaglia G, Shariat SF, Montorsi F, Saad F, Briganti A, Tilki D, Karakiewicz PI. *Eur Urol Focus*. 2017.
25. The Impact of Lymph Node Metastases Burden at Radical Prostatectomy. Preisser F, Marchioni M, Nazzani S, **Bandini M**, Tian Z, Pompe RS, Montorsi F, Saad F, Abdollah F, Steuber T, Heinzer H, Huland H, Graefen M, Tilki D, Karakiewicz PI. *Eur Urol Focus*. 2018.
26. Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≤ 50 years: a population-based study. Pompe RS, Smith A, **Bandini M**, Marchioni M, Martel T, Preisser F, Leyh-Bannurah SR, Schiffmann J, Saad F, Huland H, Graefen M, Shariat SF, Tilki D, Karakiewicz PI. *Prostate Cancer Prostatic Dis*. 2018.
27. Neoadjuvant and adjuvant treatment in high-risk prostate cancer. **Bandini M**, Fossati N, Gandaglia G, Preisser F, Dell'Oglio P, Zaffuto E, Stabile A, Gallina A, Suardi N, Shariat SF, Montorsi F, Karakiewicz PI, Briganti A. *Expert Rev Clin Pharmacol*. 2018.
28. Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients. **Bandini M**, Preisser F, Nazzani S, Marchioni M, Tian Z, Fossati N, Gandaglia G, Gallina A, Abdollah F, Shariat SF, Montorsi F, Saad F, Tilki D, Briganti A, Karakiewicz PI. *Eur Urol Focus*. 2018.

29. Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years. Marchioni M, Preisser F, **Bandini M**, Nazzani S, Tian Z, Kapoor A, Cindolo L, Abdollah F, Tilki D, Briganti A, Montorsi F, Shariat SF, Schips L, Karakiewicz PI. *Eur Urol Focus*. 2018.
30. External beam radiotherapy with or without androgen deprivation therapy in elderly patients with high metastatic risk prostate cancer. Dell'Oglio P, **Bandini M**, Leyh-Bannurah SR, Tian Z, Trudeau V, Larcher A, Fossati N, Moschini M, Gandaglia G, Capitanio U, Briganti A, Graefen M, Montorsi F, Saad F, Karakiewicz PI. *Urol Oncol*. 2018.
31. Therapeutic strategies for organ-confined and non-organ-confined bladder cancer after radical cystectomy. Marchioni M, Nazzani S, Preisser F, **Bandini M**, Karakiewicz PI. *Expert Rev Anticancer Ther*. 2018.
32. Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature. **Bandini M**, Smith A, Marchioni M, Pompe RS, Martel TF, Cindolo L, Montorsi F, Shariat SF, Briganti A, Kapoor A, Capitanio U, Karakiewicz PI. *Clin Genitourin Cancer*. 2018.
33. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. Preisser F, **Bandini M**, Marchioni M, Nazzani S, Tian Z, Pompe RS, Fossati N, Briganti A, Saad F, Shariat SF, Heinzer H, Huland H, Graefen M, Tilki D, Karakiewicz PI. *Prostate*. 2018.
34. Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogram. Pompe RS, **Bandini M**, Preisser F, Marchioni M, Zaffuto E, Tian Z, Salomon G, Schlomm T, Huland H, Graefen M, Tilki D, Shariat SF, Karakiewicz PI. *Prostate Cancer Prostatic Dis*. 2018.
35. Local treatment for metastatic prostate cancer: A systematic review. Tilki D, Pompe RS, **Bandini M**, Marchioni M, Kretschmer A, Tian Z, Karakiewicz PI, Evans CP. *Int J Urol*. 2018
36. The effect of age on cancer-specific mortality in patients with small renal masses: A population-based analysis. **Bandini M**, Marchioni M, Pompe RS, Tian Z, Martel T, Chun FK, Cindolo L, Kapoor A, Montorsi F, Shariat SF, Briganti A, Karakiewicz PI. *Can Urol Assoc J*. 2018.

37. Reply to the letter to the editor: RE: Preisser F, et al. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. *The Prostate*. 2018;1-7. Preisser F, **Bandini M**, Graefen M, Tilki D, Karakiewicz PI. *Prostate*. 2018.
38. A contemporary analysis of radiotherapy effect in surgically treated retroperitoneal sarcoma. Nazzani S, **Bandini M**, Marchioni M, Preisser F, Tian Z, Soulières D, Montanari E, Motta G, Acquati P, Briganti A, Shariat SF, Abdollah F, Carmignani L, Karakiewicz PI. *Radiother Oncol*. 2018.
39. Anastomotic leaks and catheter time after salvage robot-assisted radical prostatectomy. **Bandini M**, Gandaglia G, Fossati N, Montorsi F, Briganti A. *Transl Androl Urol*. 2018.
40. Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages. Pompe RS, Tilki D, Preisser F, Leyh-Bannurah SR, **Bandini M**, Marchioni M, Gild P, Tian Z, Fossati N, Cindolo L, Shariat SF, Huland H, Graefen M, Briganti A, Karakiewicz PI. *Prostate*. 2018.
41. Contemporary rates of adherence to international guidelines for pelvic lymph node dissection in radical cystectomy: a population-based study. Zaffuto E, **Bandini M**, Gazdovich S, Valiquette AS, Leyh-Bannurah SR, Tian Z, Dell'Oglio P, Graefen M, Moschini M, Necchi A, Shariat SF, Briganti A, Montorsi F, Karakiewicz PI. *World J Urol*. 2018.
42. Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma. Marchioni M, Harmouch SS, Nazzani S, **Bandini M**, Preisser F, Tian Z, Kapoor A, Cindolo L, Briganti A, Shariat SF, Schips L, Karakiewicz PI. *Cancer Epidemiol*. 2018.
43. Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer. **Bandini M**, Marchioni M, Preisser F, Zaffuto E, Tian Z, Tilki D, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI. *World J Urol*. 2018.

44. The Effect of Institution Teaching Status on Perioperative Outcomes After Robotic Partial or Radical Nephrectomy. Marchioni M, Nazzani S, Preisser F, **Bandini M**, Tian Z, Kapoor A, Cindolo L, Primiceri G, Carmignani L, Briganti A, Montorsi F, Shariat SF, Schips L, Karakiewicz PI. *J Endourol*. 2018.
45. Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database. Preisser F, **Bandini M**, Mazzone E, Nazzani S, Marchioni M, Tian Z, Saad F, Pompe RS, Shariat SF, Heinzer H, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI. *Eur Urol Focus*. 2018.
46. Comparison of Perioperative Outcomes Between Open and Robotic Radical Cystectomy: A Population-Based Analysis. Nazzani S, Mazzone E, Preisser F, **Bandini M**, Tian Z, Marchioni M, Ratti D, Motta G, Zorn KC, Briganti A, Shariat SF, Montanari E, Carmignani L, Karakiewicz PI. *J Endourol*. 2018.
47. Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. Karakiewicz PI, Zaffuto E, Kapoor A, Basappa NS, Bjarnason GA, Blais N, Breau RH, Canil C, Drachenberg D, Hotte SJ, Jeldres C, Jewett MAS, Kassouf W, Kollmannsberger C, Lavallée LT, Maloni R, Patenaude F, Pouliot F, Reaume MN, Sabbagh R, Shayegan B, So A, Soulières D, Tanguay S, Wood L, **Bandini M**. *Can Urol Assoc J*. 2018.
48. Increasing rate of lymph node invasion in patients with prostate cancer treated with radical prostatectomy and lymph node dissection. Preisser F, Nazzani S, **Bandini M**, Marchioni M, Tian Z, Montorsi F, Saad F, Briganti A, Steuber T, Budäus L, Huland H, Graefen M, Tilki D, Karakiewicz PI. *Urol Oncol*. 2018.
49. Location of Metastases in Contemporary Prostate Cancer Patients Affects Cancer-Specific Mortality. Mazzone E, Preisser F, Nazzani S, Tian Z, **Bandini M**, Gandaglia G, Fossati N, Soulières D, Graefen M, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI. *Clin Genitourin Cancer*. 2018.

50. Comparison of Perioperative Outcomes Between Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer. Preisser F, Mazzone E, Nazzani S, **Bandini M**, Tian Z, Marchioni M, Steuber T, Saad F, Montorsi F, Shariat SF, Huland H, Graefen M, Tilki D, Karakiewicz PI. *Eur Urol*. 2018.
51. Nomograms in urologic oncology, advantages and disadvantages. **Bandini M**, Fossati N, Briganti A. *Curr Opin Urol*. 2018.
52. Racial disparities in lymph node dissection at radical prostatectomy: A Surveillance, Epidemiology and End Results database analysis. Preisser F, Nazzani S, **Bandini M**, Marchioni M, Tian Z, Saad F, Chun FK, Shariat SF, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI. *Int J Urol*. 2018.
53. Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma. Mazzone E, Nazzani S, Preisser F, Tian Z, Marchioni M, **Bandini M**, Capitanio U, Kapoor A, Tilki D, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz P. *Cancer Epidemiol*. 2018.
54. Regional differences in total hospital charges between open and robotically assisted radical prostatectomy in the United States. Preisser F, Nazzani S, Mazzone E, Knipper S, **Bandini M**, Tian Z, Haese A, Saad F, Zorn KC, Montorsi F, Shariat SF, Graefen M, Tilki D, Karakiewicz PI. *World J Urol*. 2018.
55. The effect of race on survival after local therapy in metastatic prostate cancer patients. Mazzone E, **Bandini M**, Preisser F, Nazzani S, Tian Z, Abdollah F, Soulieres D, Graefen M, Montorsi F, Shariat S, Saad F, Briganti A, Karakiewicz P. *Can Urol Assoc J*. 2018.
56. Survival Effect of Chemotherapy in Metastatic Upper Urinary Tract Urothelial Carcinoma. Nazzani S, Preisser F, Mazzone E, Marchioni M, **Bandini M**, Tian Z, Mistretta FA, Shariat SF, Soulières D, Montanari E, Acquati P, Briganti A, Carmignani L, Karakiewicz PI. *Clin Genitourin Cancer*. 2018.
57. Increasing Rate of Noninterventional Treatment Management in Localized Prostate Cancer Candidates for Active Surveillance: A North American Population-Based Study. **Bandini M**,

Nazzani S, Marchioni M, Preisser F, Tian Z, Moschini M, Abdollah F, Suardi N, Graefen M, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI. Clin Genitourin Cancer. 2018.

58. Rates of Positive Surgical Margins and Their Effect on Cancer-specific Mortality at Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer. Preisser F, Mazzone E, Knipper S, Nazzani S, **Bandini M**, Shariat SF, Tian Z, Saad F, Montorsi F, Zorn KC, Graefen M, Tilki D, Karakiewicz PI. Clin Genitourin Cancer. 2018.
59. Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes. Gandaglia G, Soligo M, Battaglia A, Muilwijk T, Robesti D, Mazzone E, Barletta F, Fossati N, Moschini M, **Bandini M**, Joniau S, Karnes RJ, Montorsi F, Briganti A. Eur Urol. 2018.
60. North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients. Preisser F, Mazzone E, Nazzani S, Marchioni M, **Bandini M**, Tian Z, Saad F, Soulières D, Shariat SF, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI. Br J Cancer. 2018.
61. Postoperative paralytic ileus after major oncological procedures in the enhanced recovery after surgery era: A population-based analysis. Nazzani S, **Bandini M**, Preisser F, Mazzone E, Marchioni M, Tian Z, Stubinski R, Clementi MC, Saad F, Shariat SF, Montanari E, Briganti A, Carmignani L, Karakiewicz PI. Surg Oncol. 2019.
62. Survival Effect of Nephroureterectomy in Metastatic Upper Urinary Tract Urothelial Carcinoma. Nazzani S, Preisser F, Mazzone E, Marchioni M, **Bandini M**, Tian Z, Mistretta FA, Shariat SF, Soulières D, Saad F, Montanari E, Luzzago S, Briganti A, Carmignani L, Karakiewicz PI. Clin Genitourin Cancer. 2019
63. Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. **Bandini M**, Briganti A, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan U, Théodore C, Rosenberg JE, Bellmunt J, Galsky MD, Montorsi F, Necchi A. Eur Urol Oncol. 2019

64. Location of Metastatic Bladder Cancer as a Determinant of In-hospital Mortality After Radical Cystectomy. Zaffuto E, **Bandini M**, Moschini M, Leyh-Bannurah SR, Gazdovich S, Dell'Oglio P, Gallina A, Shariat SF, Briganti A, Montorsi F, Saad F, Karakiewicz PI. *Eur Urol Oncol*. 2018
65. Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer. Preisser F, Marchioni M, Nazzani S, **Bandini M**, Tian Z, Saad F, Pompe RS, Briganti A, Budäus L, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI. *Eur Urol Oncol*. 2018
66. The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients. **Bandini M**, Preisser F, Nazzani S, Marchioni M, Tian Z, Mazzone E, Graefen M, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI. *Eur Urol Oncol*. 2018
67. Surgically Treated Retroperitoneal Sarcoma: A Population-based Competing Risks Analysis. Nazzani S, Preisser F, **Bandini M**, Marchioni M, Tian Z, Soulières D, Montanari E, Ratti D, Acquati P, Briganti A, Shariat SF, Abdollah F, Carmignani L, Karakiewicz PI. *Eur Urol Oncol*. 2018
68. Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database. **Bandini M**, Mazzone E, Preisser F, Nazzani S, Zaffuto E, Marchioni M, Tian Z, Pompe RS, Tilki D, Graefen M, Shariat SF, Montorsi F, Saad F, Briganti A, Karakiewicz P. *Eur Urol Oncol*. 2018
69. Relative Contribution of Sampling and Grading to the Quality of Prostate Biopsy: Results from a Single High-volume Institution. Bravi CA, Vertosick E, Tin A, Scuderi S, Fallara G, Rosiello G, Mazzone E, **Bandini M**, Gandaglia G, Fossati N, Freschi M, Montironi R, Briganti A, Montorsi F, Vickers A. *Eur Urol Oncol*. 2018
70. The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes. Mazzone E, Preisser F, Nazzani S, Tian Z, **Bandini M**, Gandaglia G, Fossati N, Montorsi F, Graefen M, Shariat SF, Saad F, Briganti A, Karakiewicz PI. *Eur Urol Oncol*. 2019

71. Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups. Preisser F, **Bandini M**, Nazzani S, Mazzone E, Marchioni M, Tian Z, Chun FKH, Saad F, Briganti A, Haese A, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI. *Eur Urol Oncol*. 2019
72. UICC and AJCC 8th edition tumor-nodes-metastasis (TNM) classifications for patients treated with radical prostatectomy: reliable but not infallible prognostic tools. **Bandini M**, Preisser F. *Ann Transl Med*. 2
73. Editorial Comment. Pederzoli F, **Bandini M**. *J Urol*. 2019
74. Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. Pederzoli F, **Bandini M**, Briganti A, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan UN, Théodore C, Rosenberg JE, Harshman LC, Bellmunt J, Galsky MD, Gallina A, Salonia A, Montorsi F, Necchi A; RISC Investigators. *Eur Urol*. 2019
75. Comparison of Open Versus Robotically Assisted Cytoreductive Radical Prostatectomy for Metastatic Prostate Cancer. Preisser F, Nazzani S, Mazzone E, Marchioni M, **Bandini M**, Tian Z, Haese A, Saad F, Zorn K, Montorsi F, Shariat SF, Graefen M, Tilki D, Karakiewicz PI. *Clin Genitourin Cancer*. 2019
76. Salvage pelvic lymph node dissection for lymph node recurrent prostate cancer. Rosiello G, **Bandini M**, Briganti A. *Curr Opin Urol*. 2019
77. Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients. Buti S, Karakiewicz PI, Bersanelli M, Capitano U, Tian Z, Cortellini A, Taguchi S, Briganti A, Montorsi F, Leonardi F, **Bandini M**. *Sci Rep*. 2019
78. Diagnostic Value of 18F-fluorodeoxyglucose Positron Emission Tomography with Computed Tomography for Lymph Node Staging in Patients with Upper Tract Urothelial Carcinoma. Voskuilen CS, Schweitzer D, Jensen JB, Nielsen AM, Joniau S, Muilwijk T, Necchi A, Azizi M,

Spiess PE, Briganti A, **Bandini M**, Goffin K, Bouchelouche K, van Werkhoven E, Shariat SF, Xylinas E, Azawi NH, Ku JH, Foerster B, van Rhijn BWG, Vegt E, Hendricksen K. *Eur Urol Oncol*. 2019

79. Comprehensive analysis of in-hospital delirium after major surgical oncology procedures. **Bandini M**, Marchioni M, Preisser F, Nazzani S, Tian Z, Graefen M, Montorsi F, Saad F, Shariat SF, Schips L, Briganti A, Karakiewicz PI. *Can Urol Assoc J*. 2019.
80. Androgen deprivation therapy in men with node-positive prostate cancer treated with postoperative radiotherapy. Bravi CA, Tin A, Vertosick E, Mazzone E, **Bandini M**, Dell'Oglio P, Stabile A, Gandaglia G, Fossati N, Sjoberg D, Touijer K, Cozzarini C, Briganti A, Montorsi F, Eastham J, Vickers A. *Urol Oncol*. 2019.
81. Prevalence, assessment and surgical correction of penile curvature in hypospadias patients treated at one European Referral Center: description of the technique and surgical outcomes. **Bandini M**, Sekulovic S, Spiridonescu B, Krishnappa P, Dangi AD, Slavkovic M, Pesic V, Salonia A, Briganti A, Montorsi F, Djinovic R. *World J Urol*. 2019.
82. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. Necchi A, Raggi D, Gallina A, Madison R, Colecchia M, Lucianò R, Montironi R, Giannatempo P, Farè E, Pederzoli F, **Bandini M**, Bianchi M, Colombo R, Gandaglia G, Fossati N, Marandino L, Capitanio U, Dehò F, Ali SM, Chung JH, Ross JS, Salonia A, Briganti A, Montorsi F. *Eur Urol*. 2019.
83. Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy. Preisser F, Mazzone E, Knipper S, Nazzani S, **Bandini M**, Shariat SF, Marchioni M, Tian Z, Saad F, Taussky D, Briganti A, Huland H, Graefen M, Tilki D, Karakiewicz PI. *Can Urol Assoc J*. 2019.
84. Prevalence and surgical management of pubic hypertrophy in hypospadias patients: results from a high-volume surgeon. **Bandini M**, Sekulovic S, Stanojevic N, Spiridonescu B, Pesic V, Sansalone S, Slavkovic M, Briganti A, Salonia A, Montorsi F, Djinovic R. *Int Braz J Urol*. 2019.

85. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Necchi A, **Bandini M**, Calareso G, Raggi D, Pederzoli F, Farè E, Colecchia M, Marandino L, Bianchi M, Gallina A, Colombo R, Fossati N, Gandaglia G, Capitanio U, Dehò F, Giannatempo P, Lucianò R, Salonia A, Madison R, Ali SM, Chung JH, Ross JS, Briganti A, Montorsi F, De Cobelli F, Messina A. *Eur Urol*. 2019
86. Neoadjuvant chemotherapy for lymph node-positive penile cancer: current evidence and knowledge. **Bandini M**, Pederzoli F, Necchi A. *Curr Opin Urol*. 2020
87. Surgical treatment of bulbar urethral strictures: tips and tricks. Barbagli G, **Bandini M**, Balò S, Sansalone S, Butnaru D, Lazzeri M. *Int Braz J Urol*. 2020
88. Risk calculator for prediction of treatment-related urethroplasty failure in patients with penile urethral strictures. Barbagli G, **Bandini M**, Balò S, Fossati N, Montorsi F, Sansalone S, Butnaru D, Lazzeri M. *Int Urol Nephrol*. 2020
89. Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study. **Bandini M**, Pederzoli F, Madison R, Briganti A, Ross JS, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Rosenberg JE, Bellmunt J, Pal SK, Galsky MD, Lucianò R, Gallina A, Salonia A, Montorsi F, Ali SM, Chung JH, Necchi A. *Clin Genitourin Cancer*. 2020
90. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. Necchi A, Raggi D, Gallina A, Ross JS, Farè E, Giannatempo P, Marandino L, Colecchia M, Lucianò R, Bianchi M, Colombo R, Salonia A, Gandaglia G, Fossati N, **Bandini M**, Pederzoli F, Capitanio U, Montorsi F, de Jong JJ, Dittamore R, Liu Y, Davicioni E, Boormans JL, Briganti A, Black PC, Gibb EA. *Eur Urol*. 2020.
91. Optimizing the selection of candidates for neoadjuvant chemotherapy among node positive penile squamous cell carcinoma patients. **Bandini M**, Albersen M, Chipollini J, Pederzoli F, Zhu Y, Ye DW, Ornellas AA, Watkin N, Ager M, Hakenberg OW, Heidenreich A, Raggi D, Catanzaro M,

Haidl F, Mazzone E, Marandino L, Briganti A, Montorsi F, Azizi M, Spiess PE, Necchi A. *BJU Int*. 2020.

92. Reply to Yunjin Bai, Yubo Yang, Yin Tang's Letter to the Editor, re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01, Study. *Eur Urol*. In press. <http://dx.doi.org/10.1016/j.eururo.2019.12.016>. **Bandini M**, Necchi A. *Eur Urol*. 2020.
93. Re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. *Eur Urol* 2020;77:55-65. Montorsi F, **Bandini M**, Necchi A.
94. Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study. Necchi A, Raggi D, Giannatempo P, Marandino L, Farè E, Gallina A, Colecchia M, Lucianò R, Salonia A, Gandaglia G, Fossati N, **Bandini M**, Pederzoli F, Dittamore R, Liu Y, Davicioni E, Ross JS, de Jong JJ, Briganti A, Montorsi F, Gibb EA. *Eur Urol Oncol*. 2020.
95. Predicting the pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer. **Bandini M**, Ross JS, Raggi D, Gallina A, Colecchia M, Lucianò R, Giannatempo P, Farè E, Pederzoli F, Bianchi M, Colombo R, Gandaglia G, Fossati N, Marandino L, Capitanio U, Deho' F, Ali SM, Madison R, Chung JH, Salonia A, Briganti A, Montorsi F, Necchi A. *J Natl Cancer Inst*. 2020.
96. The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer. **Bandini M**, Calareso G, Raggi D, Marandino L, Colecchia M, Gallina A, Giannatempo P, Pederzoli F, Gandaglia G, Fossati N, Capitanio U, Colombo R, Salonia A, Briganti A, Montorsi F, De Cobelli F, Messina A, Necchi A. *Eur Urol Oncol*. 2020.

97. A Risk Calculator Predicting Recurrence in Lymph Node Metastatic Penile Cancer. **Bandini M**, Spiess PE, Pederzoli F, Marandino L, Brouwer OR, Albersen M, Roussel E, de Vries HM, Chipollini J, Zhu Y, Ye DW, Ornellas AA, Catanzaro M, Hakenberg OW, Heidenreich A, Haidl F, Watkin N, Ager M, Ahmed ME, Karnes JR, Briganti A, Salvioni R, Montorsi F, Azizi M, Necchi A. *BJU Int*. 2020.
98. The new era of precision urobiome: RE: "Characterization of urinary microbiome in patients with bladder cancer: Results from a single-institution, feasibility study" by Chipollini et al. Alfano M, Pederzoli F, **Bandini M**, Necchi A. *Urol Oncol*. 2020.
99. Re-establishing the Role of Robot-assisted Radical Cystectomy After the 2020 EAU Muscle-invasive and Metastatic Bladder Cancer Guideline Panel Recommendations. Montorsi F, **Bandini M**, Briganti A, Dasgupta P, Gallina A, Gallucci M, Gill IS, Guru KA, Hemal A, Menon M, Moschini M, Murphy DG, Parekh DJ, Patel HD, Patel HRH, Stöckle M, Tewari AK, Wijburg CJ, Wiklund P, Wilson TG, Mottrie A; EAU Robotic Urology Section Scientific Working Group. *Eur Urol*. 2020.
100. Patient-reported outcomes for typical single cheek harvesting vs atypical lingual, labial or bilateral cheeks harvesting: a single-center analysis of more than 800 patients. Barbagli G, **Bandini M**, Balò S, Montorsi F, Sansalone S, Dominicis M, Butnaru D, Lazzeri M. *World J Urol*. 2020.
101. Association of neurovascular bundle preservation with oncological outcomes in patients with high-risk prostate cancer. Preisser F, Gandaglia G, Arad F, Karakiewicz PI, **Bandini M**, Pompe RS, Montorsi F, Graefen M, Huland H, Briganti A, Tilki D. *Prostate Cancer Prostatic Dis*. 2020.
102. Vacuum physiotherapy after first stage buccal mucosa graft (BMG) urethroplasty in children with proximal hypospadias. **Bandini M**, Sekulovic S, Spiridonescu B, Dangi AD, Krishnappa P, Briganti A, Salonia A, Montorsi F, Djjinovic R. *Int Braz J Urol*. 2020.
103. Editorial Comment. Basile G, **Bandini M**. *J Urol*. 2020.

104. Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm? Pederzoli F, **Bandini M**, Marandino L, Raggi D, Giannatempo P, Salonia A, Gallina A, Briganti A, Montorsi F, Necchi A. *Eur Urol Oncol*. 2020.
105. Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer? Necchi A, Marandino L, Raggi D, **Bandini M**, Gallina A, Moschini M, Briganti A, Montorsi F. *Eur Urol*. 2020.
106. Re: Siamak Daneshmand, Azadeh Nazemi. Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence. *Eur Urol Focus* 2020;6:639-41. Basile G, **Bandini M**, Pederzoli F, Gallina A, Necchi A. *Eur Urol Focus*. 2020.
107. Contemporary Treatment Patterns and Outcomes for Patients with Penile Squamous Cell Carcinoma: Identifying Management Gaps to Promote Multi-institutional Collaboration. **Bandini M**, Zhu Y, Ye DW, Ornellas AA, Watkin N, Ayres B, Hakenberg OW, Heidenreich A, Raggi D, Giannatempo P, Marandino L, Haidl F, Pederzoli F, Briganti A, Montorsi F, Chipollini J, Azizi M, De Meerleer G, Brouwer OR, Grass GD, Johnstone PA, Albersen M, Spiess PE, Necchi A. *Eur Urol Oncol*. 2020.
108. Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study. **Bandini M**, Gibb EA, Gallina A, Raggi D, Marandino L, Bianchi M, Ross JS, Colecchia M, Gandaglia G, Fossati N, Pederzoli F, Lucianò R, Colombo R, Salonia A, Briganti A, Montorsi F, Necchi A. *Ann Oncol*. 2020.
109. Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally-advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase 2 PEANUT study. Giannatempo P, Raggi D, Marandino L, **Bandini M**, Farè E, Calareso G, Colecchia M, Gallina A, Ross JS, Alessi A, Briganti A, Montorsi F, Madison R, Necchi A. *Ann Oncol*. 2020.
110. Prognostic Role of Early Interim Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced Seminoma Undergoing Standard Treatment. Raggi D, **Bandini M**, Giannatempo P, Farè E, Marandino L, Colecchia M, Calareso G, Padovano B, Serafini G, Alessi A, Necchi A. *Clin Genitourin Cancer*. 2020.

111. The Performance of Tumor Size as Risk Stratification Parameter in Upper Tract Urothelial Carcinoma (UTUC). Foerster B, Abufaraj M, Mari A, Seisen T, **Bandini M**, Schweitzer D, Czech AK, Moschini M, D'Andrea D, Bianchi M, Hendricksen K, Rouprêt M, Briganti A, van Rhijn BWG, Chłosta P, Colin P, John H, Shariat SF. Clin Genitourin Cancer. 2020.
112. Targetable gene fusions and aberrations in genitourinary oncology. Pederzoli F, **Bandini M**, Marandino L, Ali SM, Madison R, Chung J, Ross JS, Necchi A. Nat Rev Urol. 2020.
113. [18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab. Marandino L, Capozza A, **Bandini M**, Raggi D, Farè E, Pederzoli F, Gallina A, Capitano U, Bianchi M, Gandaglia G, Fossati N, Colecchia M, Giannatempo P, Serafini G, Padovano B, Salonia A, Briganti A, Montorsi F, Alessi A, Necchi A. Urol Oncol. 2020.
114. Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy. Marandino L, Capozza A, **Bandini M**, Raggi D, Farè E, Pederzoli F, Gallina A, Capitano U, Bianchi M, Gandaglia G, Fossati N, Colecchia M, Giannatempo P, Serafini G, Padovano B, Salonia A, Briganti A, Montorsi F, Alessi A, Necchi A. Eur Urol Focus. 2020.
115. Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma. **Bandini M**, Ross JS, Zhu Y, Ye DW, Ornellas AA, Watkin N, Ayres BA, Hakenberg OW, Heidenreich A, Salvioni R, Catanzaro M, Raggi D, Giannatempo P, Marandino L, Haidl F, Pederzoli F, Briganti A, Montorsi F, Chipollini J, Azizi M, De Meerleer G, Brouwer OR, Grass GD, Johnstone PA, Albersen M, Spiess PE, Necchi A. Eur Urol Oncol. 2020.
116. Revolutionizing care for rare genitourinary tumours. Necchi A, Pederzoli F, **Bandini M**, Spiess PE. Nat Rev Urol. 2020.
117. Re: Hugh Mostafid, Ashish M. Kamat, Siamak Daneshmand, et al. Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours. Eur Urol Oncol. In press.

<https://doi.org/10.1016/j.euo.2020.06.010>. Montorsi F, **Bandini M**, Moschini M, Dehò F, Gallina A. *Eur Urol Oncol*. 2020.

118. Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand? Basile G, Pederzoli F, **Bandini M**, Raggi D, Gallina A, Salonia A, Briganti A, Montorsi F, Spiess PE, Necchi A. *Urol Oncol*. 2021.
119. Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study. Marcq G, Foerster B, Abufaraj M, Matin SF, Azizi M, Gupta M, Li WM, Seisen T, Clinton T, Xylinas E, Mir MC, Schweitzer D, Mari A, Kimura S, **Bandini M**, Mathieu R, Ku JH, Guruli G, Grabbert M, Czech AK, Muilwijk T, Pycha A, D'Andrea D, Petros FG, Spiess PE, Bivalacqua T, Wu WJ, Rouprêt M, Krabbe LM, Hendricksen K, Egawa S, Briganti A, Moschini M, Graffelle V, Autorino R, John P, Heidenreich A, Chlosta P, Joniau S, Soria F, Pierorazio PM, Shariat SF, Kassouf W. *Eur Urol Focus*. 2021.
120. Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab. Necchi A, de Jong JJ, Raggi D, Briganti A, Marandino L, Gallina A, **Bandini M**, Dabbas B, Davicioni E, Capitanio U, Montorsi F, Seiler R, Wright JL, Lotan Y, Black PC, Gibb EA. *Eur Urol*. 2021.
121. Incidental Prostate Cancer (cT1a-cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines. Capitanio U, Autorino R, **Bandini M**, Briganti A, Cheng L, Cooperberg MR, Dehò F, Gallina A, Klotz L, Lane B, Montironi R, Salonia A, Stief C, Tombal B, Montorsi F. *Eur Urol Oncol*. 2021.
122. Re: Francesco Soria, Marco Moschini, David D'Andrea, et al. Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. *Eur Urol Focus* 2020;6:1233-9. Montorsi F, **Bandini M**, Necchi A. *Eur Urol Focus*. 2021.
123. Assessing in-hospital morbidity after urethroplasty using the European Association of Urology Quality Criteria for standardized reporting. **Bandini M**, Barbagli G, Leni R, Cirulli GO,

Basile G, Balò S, Montorsi F, Sansalone S, Salonia A, Briganti A, Butnaru D, Lazzeri M. *World J Urol.* 2021.

124. Optimal Pathologic Response After Neoadjuvant Chemotherapy For Muscle-Invasive Bladder Cancer: Results From A Global, Multi-Center Collaboration. Ravi P, Pond GR, Diamantopoulos LN, Su C, Alva A, Jain RK, Skelton WP, Gupta S, Tward JD, Olson KM, Singh P, Grunewald CM, Niegisch G, Lee JL, Gallina A, **Bandini M**, Necchi A, Mossanen M, McGregor BA, Curran C, Grivas P, Sonpavde GP. *BJU Int.* 2021.
125. Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study Foerster B, Abufaraj M, Matin SF, Azizi M, Gupta M, Li WM, Seisen T, Clinton T, Xylinas E, Mir MC, Schweitzer D, Mari A, Kimura S, **Bandini M**, Mathieu R, Ku JH, Marcq G, Guruli G, Grabbert M, Czech AK, Muilwijk T, Pycha A, D'Andrea D, Petros FG, Spiess PE, Bivalacqua T, Wu WJ, Rouprêt M, Krabbe LM, Hendricksen K, Egawa S, Briganti A, Moschini M, Graffelle V, Kassouf W, Autorino R, Heidenreich A, Chlosta P, Joniau S, Soria F, Pierorazio PM, Shariat SF. *Eur Urol.* 2021.
126. Patterns of Recurrence Following Inguinal Lymph Node Dissection for Penile Cancer: Optimizing Surveillance Strategies. Chakiryan NH, Dahmen A, **Bandini M**, Pederzoli F, Marandino L, Albersen M, Roussel E, Zhu Y, Ye DW, Ornellas AA, Catanzaro M, Hakenberg OW, Heidenreich A, Haidl F, Watkin N, Ager M, Chahoud J, Briganti A, Salvioni R, Montorsi F, Necchi A, Spiess PE. *J Urol.* 2021.
127. Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab? Pederzoli F, **Bandini M**, Raggi D, Marandino L, Basile G, Alfano M, Colombo R, Salonia A, Briganti A, Gallina A, Montorsi F, Necchi A. *Eur Urol.* 2021.
128. Reply to Nicolas Mottet, Olivier Rouviere, and Theodorus H. van der Kwast. Incidental Prostate Cancer: A Real Need for Expansion in Guidelines? *Eur Urol Oncol.* In press: Incidental Prostate Cancer: An Example of How Important Guidelines Are, Especially When Evidence Is Limited. Capitanio U, Autorino R, **Bandini M**, Briganti A, Cheng L, Cooperberg MR, Dehò F, Gallina A, Klotz L, Lane BR, Montironi R, Salonia A, Stief C, Tombal B, Montorsi F. *Eur Urol Oncol.* 2021

129. High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors? Fallara G, **Bandini M**, Larcher A, Pederzoli F, Karakiewicz P, Tian Z, Briganti A, Necchi A, Salonia A, Bertini R, Montorsi F, Bex A, Capitanio U. *Curr Probl Cancer*. 2021.
130. A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02. Necchi A, Martini A, Raggi D, Cucchiara V, Colecchia M, Lucianò R, Villa L, Mazzone E, Basile G, Scuderi S, Pederzoli F, **Bandini M**, Barletta F, Larcher A, Capitanio U, Salonia A, Briganti A, Ross JS, Messina A, Montorsi F. *Urol Oncol*. 2021.
131. Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). Bersanelli M, Buti S, Cortellini A, **Bandini M**, Banna GL, Pederzoli F, Farè E, Raggi D, Giannatempo P, De Giorgi U, Basso U, Losanno T, Santini D, Mucciarini C, Tucci M, Tambaro R, Farnesi A, Caffo O, Veccia A, Naglieri E, Briganti A, Procopio G, Pignata S, Necchi A. *Clin Med Insights Oncol*. 2021.
132. Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition. Necchi A, Raggi D, Gallina A, **Bandini M**, de Jong JJ, Marandino L, Briganti A, Montorsi F, Davicioni E, Lotan Y, Gibb EA. *Urol Oncol*. 2021.
133. Reply by Authors. Chakiryan NH, Dahmen A, **Bandini M**, Pederzoli F, Marandino L, Albersen M, Roussel E, Zhu Y, Ye DW, Ornellas AA, Catanzaro M, Hakenberg OW, Heidenreich A, Haidl F, Watkin N, Ager M, Chahoud J, Briganti A, Salvioni R, Montorsi F, Necchi A, Spiess PE. *J Urol*. 2021.
134. Challenging the dogma of 6 steps for anastomotic urethroplasty in posterior urethral stricture: introducing step 3a. Joshi P, **Bandini M**, Montorsi F, Kulkarni SB. *World J Urol*. 2021.

135. Causal contributors to tissue stiffness and clinical relevance in urology. Martinez-Vidal L, Murdica V, Venegoni C, Pederzoli F, **Bandini M**, Necchi A, Salonia A, Alfano M. *Commun Biol*. 2021.
136. Risk factors and survival outcomes for upstaging after inguinal lymph node dissection for cN1 penile squamous cell carcinoma. Chakiryan NH, Dahmen A, **Bandini M**, Pederzoli F, Marandino L, Albersen M, Roussel E, Zhu Y, Ye DW, Ornellas AA, Catanzaro M, Hakenberg OW, Heidenreich A, Haidl F, Watkin N, Ager M, Briganti A, Salvioni R, Montorsi F, Necchi A, Spiess PE. *Urol Oncol*. 2021.
137. Re: Sanad Saad, Nadir I. Osman, Christopher R. Chapple. Female Urethra: Is Ventral the True Dorsal? *Eur Urol* 2020;78:e218-9. Kulkarni SB, Joshi PM, **Bandini M**, Morey AF, Santucci RA, Fisch M, Djinovic R, Montorsi F, Barbagli G, Mundy T. *Eur Urol*. 2021
138. Bladder-sparing combination treatments for muscle-invasive bladder cancer: A plea for standardized assessment and definition of clinical trials endpoints. Basile G, **Bandini M**, Raggi D, Marandino L, Pederzoli F, Salonia A, Briganti A, Montorsi F, Kulkarni SB, Necchi A. *Urol Oncol*. 2021.
139. Graft Plus Fasciocutaneous Penile Flap for Nearly or Completely Obliterated Long Bulbar and Penobulbar Strictures. Joshi PM, **Bandini M**, Bafna S, Sharma V, Patil A, Bhadravar S, Yepes C, Barbagli G, Montorsi F, Kulkarni SB. *Eur Urol Open Sci*. 2021.
140. A global approach to improving penile cancer care. **Bandini M**, Ahmed M, Basile G, Watkin N, Master V, Zhu Y, Prakash G, Rodriguez A, Sebakumba MK, Leni R, Cirulli GO, Ayres B, Compitello R, Pederzoli F, Joshi PM, Kulkarni SB, Montorsi F, Sonpavde G, Necchi A, Spiess PE. *Nat Rev Urol*. 2021.
141. Comprehensive Analysis of Pediatric Pelvic Fracture Urethral Injury-Reconstructive Center Experience. Sreeranga YL, Joshi PM, **Bandini M**, Kulkarni SB. *BJU Int*. 2022.
142. Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study. Grossmann NC, Pradere B, D'Andrea D, Schuettfort VM, Mori K, Rajwa P, Quhal F, Laukhtina E, Katayama S, Fankhauser CD, Xylinas

- E, Margulis V, Moschini M, Abufaraj M, **Bandini M**, Lonati C, Nyirady P, Karakiewicz PI, Fajkovic H, Shariat SF. Clin Genitourin Cancer. 2022.
143. How to get involved in clinical research: helpful tips. Diaz KA, Spiess PE, Necchi A, Li R, **Bandini M**, García-Perdomo HA. Can J Urol. 2022.
144. Dorsal approach for double-face bulbar urethroplasty: ventral inlay plus dorsal onlay using Kulkarni one-side dissection. Ballesteros Ruiz C, **Bandini M**, Joshi PM, Bafna S, Sharma V, Yatam SL, Bhadranavar S, Patil A, Kulkarni SB. Int Urol Nephrol. 2022
145. Mucosal-sparing augmented non-transected anastomotic (MsANTA) urethroplasty: a step forward in ANTA urethroplasty. Joshi P, **Bandini M**, Kulkarni SB. BJU Int. 2022
146. Editorial Comment. **Bandini M**, Basile G. J Urol. 2022 May
147. The Impact of Surgical Volume on Perioperative Safety After Urethroplasty: a population-based study. Basile G, Karakiewicz PI, Tian Z, Djinović R, Montorsi F, Barbagli G, Joshi P, Kulkarni SB, **Bandini M**. Minerva Urol Nephrol. 2022.
148. Which are the commonest sites and characteristics of post- transurethral prostate surgery (TPS) strictures in a high-volume reconstructive center? **Bandini M**, Yepes C, Joshi PM, Basile G, Naranjo D, Bhadranavar S, Alrefaey A, Bafna S, Montorsi F, Kulkarni SB. J Endourol. 2022.
149. Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study. Necchi A, Spiess PE, **Bandini M**, Basile G, Grivas P, Bratslavsky G, Jacob J, Danziger N, Lin D, Decker B, Sokol ES, Huang RSP, Kulkarni SB, Ross JS. Oncologist. 2022.
150. Common Flaps in Genitourinary Reconstruction. Joshi PM, **Bandini M**, Kulkarni SB. Urol Clin North Am. 2022.
151. Optimizing decision-making after ventral onlay buccal mucosa graft urethroplasty failure. **Bandini M**, Basile G, Lazzeri M, Montorsi F, Valli B, Balò S, Barbagli G. BJU Int. 2022.

152. Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial. Basile G, **Bandini M**, Gibb EA, Ross JS, Raggi D, Marandino L, Costa de Padua T, Crupi E, Colombo R, Colecchia M, Lucianò R, Nocera L, Moschini M, Briganti A, Montorsi F, Necchi A. *Clin Cancer Res*. 2022.
153. HPV vaccination and HPV-related malignancies: impact, strategies and optimizations toward global immunization coverage. Giannone G, Giuliano AR, **Bandini M**, Marandino L, Raggi D, Earle W, Ayres B, Pettaway CA, McNeish IA, Spiess PE, Necchi A. *Cancer Treat Rev*. 2022.
154. Concomitant vs Staged Therapeutic Inguinal Lymphadenectomy in Clinically Node Positive Penile Squamous Cell Carcinoma: Does It Make a Difference? Huelster HL, Chang A, Rose K, **Bandini M**, Albersen M, Roussel E, Chipollini J, Zhu Y, Ye DW, Ornellas AA, Catanzaro M, Marandino L, Pederzoli F, Hakenberg OW, Heidenreich A, Haidl F, Watkin N, Ager M, Ahmed ME, Karnes JR, Briganti A, Kim Y, Montorsi F, Necchi A, Spiess PE. *J Urol*. 2023.
155. Reply to Chao Quan, Jinbo Chen, and Jiao Hu's Letter to the Editor re: Giuseppe Basile, Marco Bandini, Ewan A. Gibb, et al. Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer: 3-Year Median Follow-up Update of PURE-01 Trial. *Clin Cancer Res* 2022;28:5107-14. Basile G, **Bandini M**, Montorsi F, Necchi A. *Eur Urol*. 2023.
156. Is chemoradiotherapy worth it in metastatic seminoma as first-line treatment? **Bandini M**, Nini A, Briganti A, Necchi A, Montorsi F. *Lancet Oncol*. 2023.
157. Management of Pelvic Fracture Urethral Injury: Is Supracrural Urethral Rerouting (Step 4) Becoming Anecdotal or Does It Remain in Force? Yepes C, Oszczudlowski M, **Bandini M**, Joshi PM, Alrefaey A, Bhadravar S, Martins FE, Kulkarni SB. *J Clin Med*. 2023.
158. Variations in Penile Cancer Management: Results From the Global Society of Rare Genitourinary Tumors Survey. Prakash G, Arora A, **Bandini M**, Basile G, Pal M, Griffiths G, Cornes R, Zhu Y, Rodriguez A, Albersen M, Necchi A, Master V, Pettaway CA, Spiess PE. *Clin Genitourin Cancer*. 2023.

159. Novel single-stage preputial spiral graft for panurethral stricture: a step-by-step description of the technique. Kulkarni SB, Joshi PM, Basile G, **Bandini M**. *World J Urol*. 2023.
160. Radical cystectomy in bladder cancer patients previously treated for prostate cancer: Insights from a large European multicentric series. Tappero S, Chierigo F, Parodi S, **Bandini M**, Moschini M, Cucchiara V, Chessa F, Di Maida F, Mari A, Manfredi M, Mantica G, Cerruto MA, Fiori C, Schiavina R, Briganti A, Suardi N, Brunocilla E, Antonelli A, Porpiglia F, Minervini A, Montorsi F, Terrone C. *Surg Oncol*. 2023.
161. Predicting Limited Survival Following Inguinal Lymph Node Dissection in Penile Cancer: Should We Revisit the Goals of Care? Hugar LA, Peak TC, Naqvi M, Kim Y, **Bandini M**, Pederzoli F, Marandino L, Albersen M, Roussel E, Zhu Y, Ye DW, Ornellas AA, Catanzaro M, Hakenberg OW, Heidenreich A, Haidl F, Watkin N, Ager M, Briganti A, Salvioni R, Chakiryan NH, Montorsi F, Necchi A, Spiess PE. *Urology*. 2023.
162. Future Directions in Urethroplasty: Emphasizing Mucosal Preservation and Reducing Graft Dependency. **Bandini M**, Joshi P, Kulkarni SB. *BJU Int*. 2023.
163. Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer. Pederzoli F, Riba M, Venegoni C, Marandino L, **Bandini M**, Alchera E, Locatelli I, Raggi D, Giannatempo P, Provero P, Lazarevic D, Moschini M, Lucianò R, Gallina A, Briganti A, Montorsi F, Salonia A, Necchi A, Alfano M. *Eur Urol*. 2024.
164. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer. Li R, Nocera L, Rose KM, Raggi D, Naidu S, Mercinelli C, Cigliola A, Tateo V, Patanè D, Grass GD, Gilbert SM, Sexton WJ, **Bandini M**, Moschini M, Briganti A, Montorsi F, Spiess PE, Necchi A. *Eur Urol Oncol*. 2024.
165. Re: Laura Elst, Manon T.A. Vreeburg, Hielke Martijn de Vries, et al. Corporal Skip Metastases in Penile Squamous Cell Carcinoma: An Unknown and Distinct Pattern of Spread

with Poor Prognosis. *Eur Urol Oncol*. In press. <https://doi.org/10.1016/j.euo.2023.09.005>.

Bandini M, Salonia A, Montorsi F. *Eur Urol Oncol*. 2024.

166. Oncological and Functional Outcomes of Penile Shaft Sparing Surgery for Localised Penile Cancer: A Systematic Review. Fallara G, Basile G, Poterek A, Tozzi M, Pang KH, Çakir OO, **Bandini M**, Ferro M, Musi G, Satchi M, Territo A, Fankhauser C, Castiglione F; EAU-YAU Penile and Testis Cancer Working Group. *Eur Urol Focus*. 2024.
167. Topographic modification of the extracellular matrix precedes the onset of bladder cancer. Venegoni C, Pederzoli F, Locatelli I, Alchera E, Martinez-Vidal L, Di Coste A, **Bandini M**, Necchi A, Montorsi F, Salonia A, Moschini M, Jose J, Scarfò F, Lucianò R, Alfano M. *Matrix Biol Plus*. 2024.
168. Total bulbospongiosum muscle sparing for bulbar urethroplasty: beyond the one-sided dissection. Joshi P, Albanese N, Bhadranaar S, Cattafi F, Salonia A, Montorsi F, Kulkarni S, **Bandini M**. *BJU Int*. 2024.
169. Double-face urethroplasty in patients with obliterative bulbar strictures post-transurethral resection of the prostate mid-term outcomes in high-volume referral center. Joshi PM, Hevia M, Sreeranga YL, **Bandini M**, Patil A, Bhadranaar S, Sharma V, Bafna S, Kulkarni SB. *Asian J Urol*. 2023.
170. Penile cancer: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up. Muneer A, **Bandini M**, Compérat E, De Meerleer G, Fizazi K, Gietema J, Gillessen S, Kirkham A, Sangar V, Alifrangis C, Powles T; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Penile cancer: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up. *ESMO Open*. 2024
171. Management of Small Testicular Masses: A Delphi Consensus Study. Pang KH, Fallara G, Lobo J, Alnajjar HM, Sangar V, von Stempel C, Huang DY, Parnham A, Cazzaniga W, Giganti F, Haider A, Sachdeva A, Albersen M, Alifrangis C, **Bandini M**, Castiglione F, De Vries HM, Fankhauser C, Heffernan Ho D, Nicol D, Shamash J, Thomas A, Walkden M, Freeman A, Muneer A; EAU-YAU Penile and Testis Cancer Working Group. *Eur Urol Oncol*. 2024.

172. Gold standard nephroureterectomy, chemoprophylaxis and surveillance in upper tract urothelial carcinoma. Basile G, **Bandini M**, Li R, Poch MA, Necchi A, Spiess PE. *Curr Opin Urol.* 2024